These include (i) older age at presentation, (ii) dominant cutaneous involvement in the absence of demonstrable involvement of bone marrow, (iii) lack of significant peripheral lymphadenopathy, and (iv) ALK negative, intense, and Golgi zone CD30 positivity in >75% tumor cells (in contrast to focal positivity in PTCL-NOS) [7]. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.